AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE

Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants ...
Seeking Alpha

TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE

THOUSAND OAKS, Calif., Sept. 24, 2024 /PRNewswire/ -- Amgen (AMGN) today announced TEPEZZA ® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high ...

Amgen reports positive Phase III findings for subcutaneous Tepezza trial

The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.
Nasdaq

Amgen's TEPEZZA Approved In Japan For Treatment Of Active Thyroid Eye Disease

(RTTNews) - Amgen (AMGN) said that Japan's Ministry of Health, Labour and Welfare approved TEPEZZA (Teprotumumab) for the treatment of active or high clinical activity score (CAS) Thyroid Eye Disease ...
WebMD

Tepezza for Thyroid Eye Disease

Doses of Tepezza are given by an intravenous infusion through a blood vessel in your arm. This infusion is usually given at a hospital, health care provider’s office, or infusion center. Sometimes you ...
FierceBiotech

Viridian's drug resolves eye disease symptoms in phase 3, advancing push to topple Amgen's Tepezza

Viridian Therapeutics’ phase 3 thyroid eye disease (TED) clinical trial has hit its primary and secondary endpoints. But with Amgen’s Tepezza already on the market, the data leave scope to question ...
Pharmabiz

Amgen announces positive phase 3 results for subcutaneous Tepezza in adults living with moderate-to-severe active thyroid eye disease

Amgen announces positive phase 3 results for subcutaneous Tepezza in adults living with moderate-to-severe active thyroid eye disease: Thousand Oaks, California Wednesday, April 8 ...